News Column

Capnia Appoints William G. Harris to its Board of Directors

July 1, 2014



"Bill Harris has built value in multiple emerging life science companies with his skills in financial strategy, fundraising, and financial operations," stated Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. "We look forward to Bill's valuable contributions as we launch the CoSense™ diagnostic device later this year, and develop additional future diagnostic products based on our Sensalyze technology."


"Through extensive experience as a financial executive in the life sciences, Bill understands the key elements necessary for building a successful business in our industry," said Ernest Mario, Ph.D., Chairman of the Board. "We look forward to having his perspectives as a Director, and to leveraging his expertise as Capnia transitions to a commercial company later this year."


"I believe Capnia's CoSense product and Sensalyze™ Technology Platform provide significant opportunities to build a diagnostics franchise over the next several years," stated Mr. Harris. "I am excited to join the Capnia's Board of Directors and look forward to contributing to the Company's future success."


Since 2001, Mr. Harris has been the Senior Vice President of Finance and Chief Financial Officer of Xenoport, Inc. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., a biotechnology company which was acquired by Corixa in 2000, the most recent of which was Senior Vice President and Chief Financial Officer. Prior to Coulter Pharmaceutical, Mr. Harris held several positions at Gilead Sciences, Inc., the most recent of which was director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration.


About CoSense


CoSense aids in the diagnosis of hemolysis, a dangerous condition in which red blood cells degrade rapidly. Hemolysis, when it occurs in neonates, can lead to long-term developmental disability. CoSense is 510(k) cleared for sale in the U.S., and received CE Mark approval for sale in the E.U. Capnia anticipates commercializing CoSense in the second half of 2014.



For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Global Data Point


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters